Navigation Links
Sequenom to Present at Two Financial Conferences in November
Date:11/5/2010

SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced that company management will present an overview of the company at the following conferences in November.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

  • Lazard Capital Markets 7th Annual Healthcare Conference
    • Location: The St. Regis, New York, NY
    • Presentation date: Tuesday November 16, 2010
    • Presentation time: 11:25am ET
    • Presenter: Harry F. Hixson Jr PhD, Chairman and CEO

  • Stephens Fall Investment Conference
    • Location: The Palace Hotel, New York, NY
    • Presentation date: Wednesday November 17, 2010
    • Presentation time: 1:00pm ET
    • Presenter: Harry F. Hixson Jr PhD, Chairman and CEO

A live webcast and 30-day archive of these presentations will be available at http://ir.sequenom.com.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a website at http://www.sequenom.com to whi
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
2. Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
3. Sequenom Announces Addition to Clinical Advisory Board
4. Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
5. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
6. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
7. Sequenom Announces Final Approval of Settlement in Class Action Securities Lawsuit
8. Sequenom to Present at the Jefferies 2010 Global Life Sciences Conference
9. Sequenom Announces Date of Second Quarter 2010 Financial Results and Conference Call
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... THOUSAND OAKS, Calif., July 29, 2014 Amgen ... for the second quarter of 2014. Key results include: ... million, with 8 percent product sales growth driven by ... (etanercept), Kyprolis ® (carfilzomib), Prolia ® (denosumab) ... grew 25 percent to $2.37, driven by higher revenues ...
(Date:7/29/2014)... LOUIS, July 29, 2014  Express Scripts Holding Company ... net income attributable to Express Scripts stockholders of $515.2 ... diluted share, as detailed in Table 4, was $1.23 ... are well positioned to serve our clients with scale, alignment ... to improve the health outcomes of our members," stated George ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... but,Underscore Need for Improved Patient Communication, Lifestyle,Management ... Elevated,Blood Pressure, NEW YORK, May 19, 2007 ... Harris Interactive(R) for the Hypertension Education,Foundation (HEF) ... Inc. (ASH) Twenty-Second Annual Scientific Meeting,and Exposition ...
... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical,professionals ... problem of,hospital-acquired gram-negative pneumonia may have a ... candidate being,developed by Nektar Therapeutics (Nasdaq:NKTR)., Results ... the use of,NKTR-061 (Inhaled Amikacin) to treat ...
Cached Medicine Technology:Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 2Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 3Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 4Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 5Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 6Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that ... medicine specialist. Alison Freeman wanted to show her patients some ... interested in finding out more about this method can easily ... it is currently available in online format. , In the ... herbal medicine tips that can help them achieve a cure ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps Treatment Miracle review ... his condition with the use of this method too. In ... , He claimed that he was able to cure ... Since his method turned out being so effective, he decided ... , The Nasal Polyps Treatment Miracle program was created ...
(Date:7/29/2014)... 2014 Diabetes is a common condition diagnosed ... sugar levels are increased, while the production of insulin is ... pancreas and which is needed by the body to regulate ... can be very dangerous, as there are numerous complications that ... about this disorder and read a complex review of Matt ...
(Date:7/29/2014)... 29, 2014 The Natural Multiple Sclerosis ... inside story to Gary M. Levin’s cure program. ... method for this serious disorder. Levin says that multiple ... that can be found in patients. , Dr. ... For many years, Levin has worked with patients suffering ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Cure for Yeast ... sufferer who is looking for an all-natural holistic cure for ... program, Sarah Summer, says that her method is 100 percent ... Actually, this is the reason why she was so determined ... Natural Cure for Yeast Infection review indicates that ...
Breaking Medicine News(10 mins):Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2
... study accepted for publication in The Endocrine Society,s ... demonstrated a novel and accurate test for early diagnosis ... to 2,000 female live births and early diagnosis allows ... conditions including cardiac and renal problems. Turner syndrome ...
... , TUESDAY, Dec. 7 (HealthDay News) -- Electronic cigarettes ... University of California researchers say. Their study ... devices that contain nicotine, flavorings and other chemicals. The ... and Drug Administration cited five e-cigarette distributors for poor ...
... Summit and Left Main Coronary Interventions Course is ... and new developments in therapeutic procedures essential for ... coronary occlusions and left main coronary interventions. Topics ... and why to open a chronic total occlusion ...
... 7 (HealthDay News) -- The presence of a certain biomarker ... increased risk of death from all causes, a new study ... T (cTnT) -- a heart-specific protein that serves as ... cTnT levels are associated with a number of chronic diseases ...
... TUESDAY, Dec. 7 (HealthDay News) -- Teens who are allowed ... smoking than teens whose parents bar them from viewing mature ... the study authors estimated that if 10- to 14-year-olds were ... to smoke could drop two to threefold. , However, ...
... Dec. 7 (HealthDay News) -- Teens who have health problems ... friendships are stronger than they actually are, new research shows. ... took part in a 1994-1996 survey that asked them about ... teens rated their health as "excellent" or "very good." The ...
Cached Medicine News:Health News:E-Cigarettes Should Be Banned Until Made Safe: Study 2Health News:CTO Summit & Left Main Coronary Interventions Course to be held Feb. 14-16, 2011, in NYC 2Health News:New Test Links Blood Protein to Heart Disease, Diabetes Risk 2Health News:Watching R-rated Movies Ups Odds of Teens Smoking 2Health News:Watching R-rated Movies Ups Odds of Teens Smoking 3Health News:Teens' Poor Health Linked to Fewer Friends 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: